

Reported severe hypersensitivity reactions after i.v. iron administration in the European Economic Area (EEA) before and after implementation of risk minimisation measures

Authors:

Lennart Nathell¹, Annegret Gohlke², Stefan Wohlfeil³

1 Nathell Medical AB, Växthusvägen 6, 582 76 Linköping, Sweden,

2 IQVIA, Landshuter Allee 10, 80637 Munich, Germany

3 Winterthur, Switzerland

Corresponding author:

Annegret Gohlke

Dr.Annegret.Gohlke@iqvia.com

PH: +49 89 4579126423

Table S 1 Characteristics of i.v. iron compounds

	Iron sucrose [1]	Ferric carboxymaltose [2]	Ferric gluconate [3]	Iron dextran [4]	Iron (III) isomaltoside 1000 [5]
Year of first authorisation	1949	2007	1963	2001	2009
Carbohydrate shell – (non-dextran, dextran, dextran-derived) [6, 7]	non-dextran	non-dextran	non-dextran	dextran	dextran derived
Approved indication	iron deficiency	iron deficiency	iron deficiency	iron deficiency	iron deficiency
Average price in Euro in the biggest EEA countries where product is available [8]	12.5	20.0	no official price available	9.8	18.6

References

1. Vifor Pharma UK Limited. Venofer (iron sucrose) 20 mg iron / ml, solution for injection or concentrate for solution for infusion. 2019. <https://www.medicines.org.uk/emc/product/5911/smpc>. Accessed 21 Sep 2019.
2. Vifor Pharma UK Limited. Ferinject (ferric carboxymaltose). 2018. <https://www.medicines.org.uk/emc/product/5910/smpc>. Accessed 21 Sep 2019.
3. Sanofi-Aventis Deutschland GmbH. Ferrlecit® 40 mg/Ferrlecit® 62,5 mg. 2018. <https://mein.sanofi.de/produkte/Ferrlecit/Downloads?id=e730fd51-e5cf-41b4-9a09-7d4429fd8fd3>. Accessed 21 Sep 2019.
4. Pharmacosmos UK Limited. CosmoFer. 2019. <https://www.medicines.org.uk/emc/product/48/smpc>. Accessed 21 Sep 2019.
5. Pharmacosmos UK Limited. Monofer 100mg/ml solution for injection/infusion. 2019. <https://www.medicines.org.uk/emc/product/5676/smpc>. Accessed 21 Sep 2019.
6. Neiser S, Rentsch D, Dippon U, Kappler A, Weidler PG, Göttlicher J, et al. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. *Biometals*. 2015;28:615–35. doi:10.1007/s10534-015-9845-9.
7. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. *Eur J Pharm Biopharm*. 2011;78:480–91. doi:10.1016/j.ejpb.2011.03.016.
8. IHS Markit PharmOnline International (POLI). Pharmaceutical Pricing & reimbursement database. 2019. <https://ihsmarkit.com/products/international-drug-price-database.html>. Accessed 21 Sep 2019.